<DOC>
	<DOCNO>NCT02489539</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness GORE® EXCLUDER® Conformable AAA Endoprosthesis treat infrarenal aneurysm locate abdominal aorta . Performance GORE® EXCLUDER® Conformable AAA Endoprosthesis judge separate performance goal .</brief_summary>
	<brief_title>Assessment GORE® EXCLUDER® Conformable AAA Endoprosthesis Treatment Abdominal Aortic Aneurysms</brief_title>
	<detailed_description>The study design prospective , nonrandomized , international , multicenter study comprise two parallel substudies . The total subject population 190 subject 80 subject assign Short Neck Substudy 110 subject High Neck Angulation Substudy . This clinical study include fifty-six site US . Each enrol subject undergo periodic follow-up evaluation involve physical exam contrast-enhanced computed tomography ( CT ) scan specific , protocol-defined interval period five year follow GORE® EXCLUDER® Conformable AAA Endoprosthesis implant . Each Substudy evaluate report independently accord Safety Effectiveness Endpoints . No comparative analysis substudies plan .</detailed_description>
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm , Abdominal</mesh_term>
	<criteria>1 . AAA meeting follow criterion : Maximum diameter ≥50 mm Rapid growth ( &gt; 5 mm 6 month period ) Nonruptured AAA present clinical symptom 2 . Adequate anatomy receive GORE® EXCLUDER® Conformable AAA Endoprosthesis , include : Adequate iliac / femoral access Infrarenal aortic neck diameter 1632 mm Infrarenal aortic neck length ≥10 mm Aortic neck angle ≤ 90˚ Distal iliac artery seal zone ≥10 mm Iliac artery diameter 825 mm 3 . An Informed Consent Form ( ICF ) sign Subject 4 . Male infertile female 5 . Able comply Protocol requirement include followingup 6 . Life expectancy &gt; 2 year 7 . Age ≥ 21 year 1 . Mycotic rupture aneurysm 2 . Known concomitant thoracic aortic aneurysm require surgical intervention 3 . Renal insufficiency define creatinine &gt; 2.5 mg/dL patient undergo dialysis 4 . New York Heart Association ( NYHA ) class IV 5 . Aneurysmal , dissect , heavily calcify , heavily thrombose land zone ( ) 6 . Severely tortuous stenotic iliac / femoral artery 7 . Patient body habitus medical condition prevents adequate delineation aorta 8 . Participating another investigational device drug study within 1 year treatment 9 . Systemic infection may increase risk endovascular graft infection 10 . Known degenerative connective tissue disease , e.g. , Marfan EhlerDanlos Syndrome 11 . Planned concomitant surgical procedure major surgery within 30 day treatment date 12 . Known history drug abuse 13 . Known sensitivity allergy device material</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Aortic aneurysm</keyword>
	<keyword>Abdominal aorta</keyword>
	<keyword>Stent graft</keyword>
	<keyword>Aneurysm</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
</DOC>